Internal and Emergency Medicine

, Volume 7, Supplement 3, pp 185–187 | Cite as

Tuberculosis a re-emerging disease



Two billion people, nearly one-third of the population worldwide, are infected by M. tuberculosis. Since 2008, the number of foreign TB cases in Italy has overtaken native cases. Even though TB prevalently affects elderly Italian natives, the diagnosis of the disease in these subjects is difficult and frequently delayed because of the low index of suspicion due to loss of clinical experience. Moreover, the large use of TNF inhibitors has created a new risk group for the disease, highlighting the need for tougher screening practices to reduce new cases of severe TB. Immigration from high-incidence countries like Romania has increased the number of cases of multi-drug resistant TB. These cases are usually difficult to treat because of fewer treatment options and also difficulty in managing patients with adverse socioeconomic conditions such as homelessness. It is mandatory that young doctors acquire experience in the diagnosis and treatment of TB, a disease that is not so infrequent as it was a decade or two ago.


Tuberculosis MDR Foreign-born TNF inhibitors 


  1. 1.
    Tuberculosis. World Health Organization Fact sheet N°104 March 2012. Accessed 1 Jun 2012
  2. 2.
    WHO Report 2011. Global tuberculosis control. Accessed 1 Jun 2012
  3. 3.
    Rapporto Tubercolosi 2008 in Italia. Italian Ministry of Health. (in Italian). Accessed 1 Jun 2012
  4. 4.
    Fattorini L, Mustazzolu A, Piccaro G et al (2012) Drug-resistant tuberculosis among foreign-born persons in Italy. Eur Resp J 40:1–4CrossRefGoogle Scholar
  5. 5.
    Das SK, Mukherjee RS, Ghosh IN (2007) A study of pulmonary tuberculosis in the elderly. J Indian Med Assoc 105(8):432, 436, 438–439Google Scholar
  6. 6.
    Gagliotti C, Resi D, Moro ML (2006) Delay in the diagnosis of pulmonary TB in a changing demographic scenario. Int J Tuberc Lung Dis 10(3):305–309PubMedGoogle Scholar
  7. 7.
    Ginsburg AS, Woolwine SC, Hooper N et al (2003) The rapid development of fluoroquinolone resistance in M. tuberculosis. N Engl J Med 349(20):1977–1978PubMedCrossRefGoogle Scholar
  8. 8.
    Fallahi-Sichani M, Flynn JL, Linderman JJ, Kirschner DE (2012) Differential risk of tuberculosis reactivation among anti-TNF therapies is due to drug binding kinetics and permeability. J Immunol 188(7):3169–3178 (Epub 2012 Feb 29)Google Scholar
  9. 9.
    TB control guidelines 2010. Italian ministry of Health. (in Italian). Accessed 1 Jun 2012
  10. 10.
    Zhao Y, Xu S, Wang L et al (2012) National survey of drug-resistant tuberculosis in China. N Engl J Med 366(23):2161–2170PubMedCrossRefGoogle Scholar
  11. 11.
    Sotgiu G, Centis R, D’Ambrosio L (2012) Efficacy, safety and tolerability of Linezolid containing regimens in treating MDR-TB and XDR-TB: systemic review and metanalysis. Eur Respir J [Epub ahead of print]Google Scholar
  12. 12.
    Migliori GB, Zellweger JP, Abubakar I et al (2012) European union standards for tuberculosis care. Eur Respir J 39(4):807–819PubMedCrossRefGoogle Scholar
  13. 13.
    Gler MT, Skripconoka V, Sanchez-Garavito E, Xiao H et al (2012) Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 366(23):2151–2160PubMedCrossRefGoogle Scholar
  14. 14.
    Diacon AH, Donald PR, Pym A et al (2012) Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother 56(6):3271–3276 (Epub 2012 Mar 5)Google Scholar
  15. 15.
    Kempker RR, Vashakidze S, Solomonia N et al (2012) Surgical treatment of drug-resistant tuberculosis. Lancet Infect Dis 12(2):157–166PubMedCrossRefGoogle Scholar

Copyright information

© SIMI 2012

Authors and Affiliations

  1. 1.Department of Phthisiology and PulmonologyMorelli HospitalSondalo (SO)Italy

Personalised recommendations